Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1992 1
1993 1
1995 4
1996 2
1997 5
1998 5
1999 3
2000 2
2001 2
2002 1
2003 2
2004 3
2005 2
2006 2
2007 1
2014 1
2017 1
2018 1
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. Sullivan RJ, et al. Among authors: varterasian m. Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15. Cancer Discov. 2018. PMID: 29247021 Free article. Clinical Trial.
Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors.
Janku F, Zhang HH, Pezeshki A, Goel S, Murthy R, Wang-Gillam A, Shepard DR, Helgason T, Masters T, Hong DS, Piha-Paul SA, Karp DD, Klang M, Huang SY, Sakamuri D, Raina A, Torrisi J, Solomon SB, Weissfeld A, Trevino E, DeCrescenzo G, Collins A, Miller M, Salstrom JL, Korn RL, Zhang L, Saha S, Leontovich AA, Tung D, Kreider B, Varterasian M, Khazaie K, Gounder MM. Janku F, et al. Among authors: varterasian m. Clin Cancer Res. 2021 Jan 1;27(1):96-106. doi: 10.1158/1078-0432.CCR-20-2065. Epub 2020 Oct 12. Clin Cancer Res. 2021. PMID: 33046513
Trisomy 6 as a primary karyotypic aberration in hematologic disorders.
Mohamed AN, Varterasian ML, Dobin SM, McConnell TS, Wolman SR, Rankin C, Willman CL, Head DR, Slovak ML. Mohamed AN, et al. Among authors: varterasian ml. Cancer Genet Cytogenet. 1998 Oct 15;106(2):152-5. doi: 10.1016/s0165-4608(98)00057-0. Cancer Genet Cytogenet. 1998. PMID: 9797781 Review.
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.
Wu J, Liu D, Offin M, Lezcano C, Torrisi JM, Brownstein S, Hyman DM, Gounder MM, Abida W, Drilon A, Harding JJ, Sullivan RJ, Janku F, Welsch D, Varterasian M, Groover A, Li BT, Lacouture ME. Wu J, et al. Among authors: varterasian m. Invest New Drugs. 2021 Jun;39(3):785-795. doi: 10.1007/s10637-020-01035-9. Epub 2021 Jan 3. Invest New Drugs. 2021. PMID: 33389388
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.
Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein MK, Post G, Diaz LA Jr, Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C, Huso DL, Varterasian M, Saha S, Zhou S. Roberts NJ, et al. Among authors: varterasian m. Sci Transl Med. 2014 Aug 13;6(249):249ra111. doi: 10.1126/scitranslmed.3008982. Sci Transl Med. 2014. PMID: 25122639 Free PMC article.
Cardiac safety, risk management, and oncology drug development.
Fingert HJ, Varterasian ML. Fingert HJ, et al. Among authors: varterasian ml. Clin Cancer Res. 2006 Jun 15;12(12):3646-7. doi: 10.1158/1078-0432.CCR-06-0518. Clin Cancer Res. 2006. PMID: 16778090 Free article. No abstract available.
41 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page